Skip to content

Driving Biopharmaceutical Advancements of Naturally Derived and Evidence Based Products

Who We Are

Avicanna is a Canadian commercial-stage biopharmaceutical company

Leading in cannabinoid research, development, and evidence-based products for the global consumer medical and pharmaceutical segments.

Play Video
Avicanna 2022 Corporate Video

Corporate Overview

An international biopharmaceutical strategy

Proprietary portfolio products – across API, medical, cosmetics and nutraceutical segments 

Commercial scale up phase – across 19 international markets

Established USDA organic certified vertical integration infrastructure – in Santa Marta, Colombia

Leading scientific platform and intellectual property

JLABS @ Johnson & Johnson Innovation Centre graduate housed in the MaRS Discovery District

Canadian R&D and clinical infrastructure – in partnership with world-class institutions

24 proprietary SKUs commercialized – from the lab to medical and retail channels in Canada

Pharmaceutical pipeline – addressing neurological, dermatological and pain indications

Four synergistic commercial pillars and portfolio

Medical cannabis and wellness products – in commercial stage 

CBD Cosmetics and skincare – in commercial stage

Pharmaceutical pipeline – in development stage

Active pharmaceutical ingredients (API) – in commercial stage

Commercial Pillars and Portfolio

Avicanna’s scientific platform has resulted in 30+ commercial and proprietary formulations and products

Including cosmetics, medical cannabis, pharmaceuticals in addition to its raw material business unit across international markets.

Commercial Stage
Medical Cannabis and Wellness Products

Commercial Stage 
CBD Cosmetics and Skincare

In Development and Registration Stage
Pharmaceutical Pipeline

Commercial Stage
Cannabinoid API

Industry Leading Scientific Platform

Setting the Standard in the Cannabinoid Industry on Advanced and Evidence-Based Products

Scientific Platform

Setting the Standard in the Cannabinoid Industry with Advanced and Evidence-Based Products 

R&D headquarters in Toronto, Canada with drug development pipeline including sustained release tablets, transdermal patches and nano particle formulations

30+

Proprietary Commercial Products

10+

Scientists

9

Canadian Government Research Grants Awarded Since 2020

7

Pending Patents

4

Health Canada Cannabis
Research Licenses
to Avicanna
or Institutional Collaborators

World-class Institutional Collaborations

R&D and Clinical Partnerships Over the Past 4 Years

World-class Institutional Collaborations

20+ R&D, pre-clinical and research collaborations with Canada’s leading institutions and thought leaders since 2017

Majority of the research has been conducted in Canada through 4 Health Canada cannabis R&D licenses issued to Avicanna and its academic collaborators.

Clinical Development

Setting the Standard in the Cannabinoid Industry on Advanced and Evidence-Based Products

08.08.2021

Products & Pipeline

Serving the Global Marketplace with Proprietary Advanced Cannabinoid-Based Products